{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:15:43Z","timestamp":1784135743913,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004014","name":"Japan IDDM network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011307","name":"Association for Molecular Pathology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K01AA024174"],"award-info":[{"award-number":["K01AA024174"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000350","name":"Core","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ymthe.2017.08.005","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T20:30:10Z","timestamp":1502397010000},"page":"2299-2308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Qunfeng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu","family":"Le Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohui","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouhua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Puszyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kien","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ostrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranela","family":"Rameshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Qing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.08.005_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2005-871194","article-title":"Hepatocellular carcinoma: epidemiology, risk factors, and screening","volume":"25","author":"Sherman","year":"2005","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ymthe.2017.08.005_bib2","first-page":"2498","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Palmer","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.08.005_bib3","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/hep.510250511","article-title":"Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma","volume":"25","author":"Tatsumi","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2017.08.005_bib4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4049\/jimmunol.172.2.1009","article-title":"Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition","volume":"172","author":"Pillarisetty","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2017.08.005_bib5","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2017.08.005_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-204897","article-title":"Spontaneous regression of a biopsy confirmed hepatocellular carcinoma","volume":"2014","author":"Bhardwaj","year":"2014","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ymthe.2017.08.005_bib7","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/hep.24149","article-title":"Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma","volume":"53","author":"Mizukoshi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2017.08.005_bib8","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/1078-0432.CCR-05-2267","article-title":"Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma","volume":"12","author":"Komori","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.08.005_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2017.08.005_bib10","doi-asserted-by":"crossref","first-page":"e1062209","DOI":"10.1080\/2162402X.2015.1062209","article-title":"Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T\u00a0cells; prolonged overall survival in cancer patients with Th cell response","volume":"5","author":"Sayem","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2017.08.005_bib11","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.08.005_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/cas.12368","article-title":"Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma","volume":"105","author":"Ikeda","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ymthe.2017.08.005_bib13","doi-asserted-by":"crossref","first-page":"E1083","DOI":"10.1073\/pnas.1217868110","article-title":"Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma","volume":"110","author":"Feng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.08.005_bib14","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1078-0432.CCR-12-2616","article-title":"First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.08.005_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","article-title":"Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma","volume":"65","author":"Abou-Alfa","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2017.08.005_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000341697","article-title":"Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy","volume":"30","author":"Schmidt","year":"2012","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ymthe.2017.08.005_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2017.08.005_bib18","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/mt.2016.122","article-title":"Coadministration of a plasmid encoding HIV-1 gag enhances the efficacy of cancer DNA vaccines","volume":"24","author":"Lambricht","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.08.005_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ymthe.2004.05.015","article-title":"Therapeutic HER2\/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu","volume":"10","author":"Lin","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.08.005_bib20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.f.1774","article-title":"CD8+ T\u00a0cell efficacy in vaccination and disease","volume":"14","author":"Appay","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.08.005_bib21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature14320","article-title":"Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients","volume":"519","author":"Mitchell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.08.005_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.08.005_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbrc.2008.11.033","article-title":"Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells","volume":"378","author":"Nakano","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2017.08.005_bib24","doi-asserted-by":"crossref","first-page":"9832","DOI":"10.1158\/0008-5472.CAN-08-1973","article-title":"Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer","volume":"68","author":"Ishiguro","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.08.005_bib25","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-12-3381","article-title":"Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality","volume":"73","author":"Kalathil","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.08.005_bib26","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.08.005_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2017.08.005_bib28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.26996","article-title":"Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy","volume":"60","author":"Gao","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2017.08.005_bib29","doi-asserted-by":"crossref","first-page":"33878","DOI":"10.1038\/srep33878","article-title":"Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2017.08.005_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbrc.2015.10.168","article-title":"Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP100(25-33) peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma","volume":"468","author":"Chang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2017.08.005_bib31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4049\/jimmunol.1201557","article-title":"Vaccine injection site matters: qualitative and quantitative defects in CD8 T\u00a0cells primed as a function of proximity to the tumor in a murine glioma model","volume":"190","author":"Ohlfest","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2017.08.005_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2017.08.005_bib33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T\u00a0cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2017.08.005_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymthe.2005.02.012","article-title":"GM-CSF gene-transduced tumor vaccines","volume":"12","author":"Eager","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.08.005_bib35","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/sj.mt.6300149","article-title":"Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity","volume":"15","author":"Ye","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.08.005_bib36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/B978-0-12-396548-6.00004-4","article-title":"Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients","volume":"114","author":"Quakkelaar","year":"2012","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.ymthe.2017.08.005_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.intimp.2015.12.023","article-title":"Potent antigen-specific immune response induced by infusion of spleen cells coupled with succinimidyl-4-(N-maleimidomethyl cyclohexane)-1-carboxylate (SMCC) conjugated antigens","volume":"31","author":"Guo","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2017.08.005_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/wsbm.1198","article-title":"Promise of personalized omics to precision medicine","volume":"5","author":"Chen","year":"2013","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"10.1016\/j.ymthe.2017.08.005_bib39","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.08.005_bib40","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/imr.12405","article-title":"Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers","volume":"271","author":"Dieu-Nosjean","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2017.08.005_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2006.04.017","article-title":"Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming","volume":"25","author":"Allan","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2017.08.005_bib42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2017.08.005_bib43","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2017.08.005_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cytogfr.2004.11.001","article-title":"Tumor necrosis factor, cancer and anticancer therapy","volume":"16","author":"Mocellin","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2017.08.005_bib45","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/ijc.28311","article-title":"Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments","volume":"133","author":"Lee","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2017.08.005_bib46","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1440-1746.2002.02837.x","article-title":"Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma","volume":"17","author":"Matsui","year":"2002","journal-title":"J.\u00a0Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2017.08.005_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0014-4827(02)00011-3","article-title":"Downregulation of p21(waf\/cip-1) mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-gamma","volume":"282","author":"Detjen","year":"2003","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ymthe.2017.08.005_bib48","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.28549","article-title":"Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in\u00a0vitro","volume":"64","author":"Rao","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2017.08.005_bib49","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/hep.28710","article-title":"Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features","volume":"64","author":"Calderaro","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2017.08.005_bib50","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/hep.27246","article-title":"Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions","volume":"60","author":"Hato","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2017.08.005_bib51","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/j.gastro.2007.09.017","article-title":"Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system","volume":"133","author":"Zhu","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2017.08.005_bib52","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1073\/pnas.2628032100","article-title":"Lymphocyte surface thiol levels","volume":"100","author":"Sahaf","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.08.005_bib53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.antiviral.2011.10.001","article-title":"Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine","volume":"92","author":"Wu","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ymthe.2017.08.005_bib54","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3892\/ijo.2013.1793","article-title":"Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide","volume":"42","author":"Iwama","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2017.08.005_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1172\/JCI26169","article-title":"SOCS1 restricts dendritic cells\u2019 ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling","volume":"116","author":"Evel-Kabler","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2017.08.005_bib56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.22934","article-title":"The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis","volume":"50","author":"Weng","year":"2009","journal-title":"Hepatology"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617303647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617303647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T20:07:35Z","timestamp":1750363655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617303647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1525001617303647"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.08.005","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017","name":"copyright","label":"Copyright"}]}}